Hyperbaric oxygen effectively addresses the pathophysiology of long COVID: clinical review
Authors:
Open Access
- 15 February 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1354088
Abstract
Background: The World Health Organization defines long COVID as “the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation.” Estimations of approximately 50 million individuals suffer from long COVID, reporting low health-related quality of life. Patients develop ongoing persistent symptoms that continue for more than 12 weeks that are not explained by another alternative diagnosis. To date, no current therapeutics are effective in treating the underlying pathophysiology of long COVID.Discussion: A comprehensive literature search using PubMed and Google Scholar was conducted and all available articles from November 2021 to January 2024 containing keywords long covid and hyperbaric oxygen were reviewed. These published studies, including case series and randomized trials, demonstrate that utilizing Hyperbaric Oxygen Therapy (HBO) provided significant improvement in patients with long COVID.Conclusion: A large cohort of patients suffer from long COVID or post-COVID-19 syndrome after recovery from their acute infection with no effective treatment options. HBO is a safe treatment and may provide benefit for this population and should continue to be researched for adjunctive treatment of long COVID.Keywords
This publication has 31 references indexed in Scilit:
- Long COVID: major findings, mechanisms and recommendationsNature Reviews Microbiology, 2023
- Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trialNeuroImage: Clinical, 2022
- Pathological sequelae of long-haul COVIDNature Immunology, 2022
- Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severityInternational Immunopharmacology, 2022
- Observational study on the benefit of a nutritional supplement, supporting immune function and energy metabolism, on chronic fatigue associated with the SARS-CoV-2 post-infection progressClinical Nutrition ESPEN, 2021
- The four most urgent questions about long COVIDNature, 2021
- A Review of Persistent Post-COVID Syndrome (PPCS)Clinical Reviews in Allergy & Immunology, 2021
- NICE guideline on long COVIDThe Lancet Respiratory Medicine, 2021
- Lymphopenia during the COVID-19 infection: What it shows and what can be learnedImmunology Letters, 2020
- Interleukin-6 as prognosticator in patients with COVID-19Journal of Infection, 2020